LB Pharmaceuticals Inc

Contributing Author

Recent Articles by LB Pharmaceuticals Inc

Oct-06	LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB-102 with a Focus on Schizophrenia Treatment LBRX GlobeNewswire
Sep-15	LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer LBRX GlobeNewswire
Sep-03	LB Pharmaceuticals to Participate in Upcoming September Investor Events LBRX GlobeNewswire
Sep-03	LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer LBRX GlobeNewswire
Aug-11	LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update LBRX GlobeNewswire
Jul-29	LB Pharmaceuticals Announces $150 Million Private Placement LBRX +11.62% GlobeNewswire
Jul-22	LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia LBRX +10.93% GlobeNewswire
Jul-10	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) LBRX GlobeNewswire
Jun-30	LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations LBRX GlobeNewswire
May-28	LB Pharmaceuticals to Participate in Upcoming June Investor Events LBRX GlobeNewswire
May-12	LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update LBRX GlobeNewswire
Apr-22	LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia LBRX GlobeNewswire
Apr-09	LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference LBRX LBRX -7.42% GlobeNewswire
Mar-27	LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) LBRX GlobeNewswire
Mar-26	LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update LBRX GlobeNewswire
Mar-25	LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia LBRX GlobeNewswire
Mar-09	LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors LBRX GlobeNewswire
Mar-04	LB Pharmaceuticals to Participate in Upcoming March Investor Events LBRX GlobeNewswire
Feb-10	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) LBRX GlobeNewswire
Feb-05	LB Pharmaceuticals Announces $100.0 Million Private Placement LBRX +12.71% GlobeNewswire
Jan-26	LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program LBRX -6.40% GlobeNewswire
Jan-21	LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel LBRX GlobeNewswire
Jan-12	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) LBRX -8.20% GlobeNewswire
Jan-06	LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture LBRX GlobeNewswire
Dec-10	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) LBRX LBRX -5.29% GlobeNewswire
Dec-09	LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices LBRX GlobeNewswire
Nov-24	LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference LBRX +5.28% GlobeNewswire
Nov-12	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) LBRX -5.63% GlobeNewswire
Nov-12	LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer LBRX -5.63% GlobeNewswire
Nov-06	LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference LBRX GlobeNewswire
Nov-06	LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates LBRX GlobeNewswire
Oct-14	LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs LBRX GlobeNewswire
Oct-06	LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms LBRX GlobeNewswire
Sep-25	LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani LBRX GlobeNewswire

LB Pharmaceuticals Inc

Recent Articles by LB Pharmaceuticals Inc

Upgrade your Finviz experience